



Pressrelease

Lund, Sweden 2017-09-21

CLS announces poster presentation, describing preclinical work, at SITC 2017, on 8-12 November, in the US

Clinical Laserthermia Systems (CLS) (publ) has received acceptance for its abstract for a poster presentation at this year's "Society for Immunotherapy of Cancer" (SITC) conference in Maryland, USA. The abstract is titled "Anti-tumor effects and immunological response following immune stimulating interstitial laser thermotherapy" and describes the setup and initial experiences from the preclinical work that CLS has carried out during this year.

In parallel with CLS' commercialization of the TRANBERG® | Thermal Therapy System, the company has also worked to further develop and adjust the imILT® method with the aim to carry out preclinical studies using mouse models. Parts of this work will be presented in a poster format during SITC 2017, taking place on 8-12 November, at the National Harbor, Maryland, USA.

"The preclinical work is important to us since our clinical studies, as well as the ongoing development seen in research in our field, require new approaches be taken and new questions to be answered", said Jakob Axelsson, Head of Research at CLS.

CLS develops and markets the TRANBERG® | Thermal Therapy System, as well as disposable materials and methods, for heat-induced immunotherapy for safe and gentle treatment of cancerous tumors.

[Read more about SITC 2017](#)

This information is such that Clinical Laserthermia Systems AB (publ) is required to publish pursuant to the EU Market Abuse Directive. The contact person arranged for the release of this information on 21 September 2017, at 09:30 AM.

Company contact:

Lars-Erik Eriksson, CEO Clinical Laserthermia Systems AB (publ)

Tel: +46 – (0)702 – 90 33 00 E-mail: lee@clinicallaser.se

Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG® | Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Boston, MA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on www.clinicallaser.se